logo
Plus   Neg
Share
Email

Target Boosts FY19 Adj. EPS Outlook - Quick Facts

While reporting financial results for the second quarter on Wednesday, retailer Target Corp. (TGT) initiated adjusted earnings and comparable sales guidance for the third quarter as well as raised adjusted earnings guidance for the full-year 2019.

For the third quarter, Target expects comparable sales growth of 3.4 percent, with both earnings from continuing operations and adjusted earnings to be in a range of $1.04 to $1.24 per share.

Looking ahead to fiscal 2019, the retailer raised its guidance for both earnings from continuing operations and adjusted earnings to a range of $5.90 to $6.20 per share from the prior outlook range of $5.75 to $6.05 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.62 per share for the third quarter and $5.93 per share for the year. Analysts' estimates typically exclude special items.

Additionally, the company reported second-quarter comparable sales growth of 3.4 percent on traffic growth of 2.4 percent. Comparable store sales grew 1.5 percent, and comparable digital sales grew 1.8 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT
>